Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s45. https://doi.org/10.25251/skin.6.supp.45